Pattern recognition receptors of innate immunity and their application to tumor immunotherapy

Cancer Science

Volumn 101, Issue 2, 2010, Pages 313-320

  Seya, Tsukasa ^a   Shime, Hiroaki ^a   Ebihara, Takashi ^a   Oshiumi, Hiroyuki ^a   Matsumoto, Misako ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; PEPTIDE VACCINE; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; EFFECTOR CELL; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MYELOID CELLS; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASMS; RECEPTORS, PATTERN RECOGNITION; TOLL-LIKE RECEPTORS;

EID: 75649100153     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01442.x     Document Type: Review

References (68)

1. Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989, 54:1-13.
2. Seya T, Matsumoto M. The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer. Cancer Immunol Immunother 2009, 58:1175-84.
3. Akira S. Toll-like receptor signaling. J Biol Chem 2003, 278:38105-8.
4. Seya T, Akazawa T, Tsujita T, Matsumoto M. Role of Toll-like receptors in adjuvant-augmented immune therapies. Evid Based Complement Alternat Med. 2006, 3:31-8.
5. Yoneyama M, Onomoto K, Fujita T. Cytoplasmic recognition of RNA. Adv Drug Deliv Rev 2008, 60:841-6.
6. Martinon F, Gaide O, Pétrilli V, Mayor A, Tschopp J. NALP inflammasomes: a central role in innate immunity. Semin Immunopathol 2007, 29:213-29.
7. Ishii A, Kawasaki M, Matsumoto M, Tochinai S, Seya T. Phylogenetic and expression analysis of amphibian Xenopus Toll-like receptors. Immunogenetics 2007, 59:281-93.
8. De Gregorio E, D'Oro U, Wack A. Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol 2009, 21:339-45.
9. Honda K, Taniguchi T. Toll-like receptor signaling and IRF transcription factors. IUBMB Life 2006, 58:290-5.
10. Hoshino K, Kaisho T. Nucleic acid sensing Toll-like receptors in dendritic cells. Curr Opin Immunol 2008, 20:408-13.
11. Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 2008, 60:805-12.
12. Matsnmoto M, Funami K, Oshiumi H, Seya T. Toll-like receptor 3: a link between toll- like receptor, interferon and viruses. Microbiol Immunol. 2004, 48:147-54.
13. Sasai M, Shingai M, Funami K. NAK-associated protein 1 participates in both the TLR3 and the cytoplasmic pathways in type I IFN induction. J Immunol 2006, 177:8676-83.
14. Freund J, Stone SH. The effectiveness of tuberculo-glycolipid as an adjuvant in eliciting allergic encephalomyelitis and aspermatogenesis. J Immunol 1959, 82:560-7.
15. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453:1122-6.
16. Yasumoto K, Manabe H, Yanagawa E. Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin. Cancer Res 1979, 39:3262-7.
17. Uehori J, Fukase K, Akazawa T. Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2/TLR4 activation. J Immunol 2005, 174:7096-103.
18. Diner EK, Verghese M. Interstitial pneumonitis secondary to intravesical bacillus calmette-guerin for carcinoma in-situ of the bladder. Int Braz J Urol 2004, 30:400-2.
19. Absher M, Stinebring WR. Toxic properties of a synthetic doublestranded RNA. Endotoxin-like properties of poly I. C, an interferon stimulator. Nature 1969, 223:715-7.
20. Longhi MP, Trumpfheller C, Idoyaga J. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009, 206:1589-602.
21. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316:1628-32.
22. Tsuji S, Matsumoto M, Takeuchi O. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors. Infect Immun 2000, 68:6883-90.
23. Akazawa T, Masuda H, Saeki Y. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res 2004, 64:757-64.
24. Fujimoto Y, Hashimoto M, Furuyashiki M, Katsumoto M, Seya T, Suda Y, Fukase K. Lipopeptides from Staphylococcus aureus as Tlr2 Ligands: prediction with mrna expression, chemical synthesis and immunostimulatory activities. Chembiochem 2009, 10:2311-5.
25. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008, 181:5791-802.
26. Cao X. Regulatory T cells and immune tolerance to tumors. Immunol Res 2009, Sep 10. [Epub ahead of print]
27. Chaput N, Conforti R, Viaud S, Spatz A, Zitvogel L. The Janus face of dendritic cells in cancer. Oncogene 2008, 27:5920-31.
28. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000, 74:181-273.
29. Ullrich E, Bonmort M, Mignot G. Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. Cancer Res 2007, 67:851-3.
30. Nagaraj S, Gabrilovich DI. Tumor Escape Mechanism Governed by Myeloid-Derived Suppressor Cells. Cancer Res 2008, 68:2561-3.
31. Gallina G, Dolcetti L, Serafini P. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006, 116:2777-90.
32. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008, 8:279-89.
33. Akira S, Takeda K. Functions of toll-like receptors: lessons from KO mice. C R Biol 2004, 327:581-9.
34. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388:394-7.
35. Reise Sousa C. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin Immunol 2004, 16:27-34.
36. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-95.
37. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006, 311:17-58.
38. Akazawa T, Ebihara T, Okuno M. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci U S A 2007, 104:252-7.
39. Ebihara T, Azuma M, Oshiumi H, Taniguchi T, Matsumoto M, Seya T. Identification of INAM, a polyI:C-inducible membrane protein, that participates in dendritic cell-mediated natural killer cell activation. J Exp Med 2010
40. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999, 11:115-22.
41. Sasai M, Oshiumi H, Matsumoto M. Cutting Edge: NF-kB-activating kinase-associated protein 1 participates in TLR3/Toll-IL-1 homology domain-containing adapter molecule-1-mediated IFN Regulatory Factor 3 activation. J Immunol 2005, 174:27-30.
42. Meylan E, Burns K, Hofmann K. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol 2004, 5:503-7.
43. Ryzhakov G, Randow F. SINTBAD, a novel component of innate antiviral immunity, shares a TBK1-binding domain with NAP1 and TANK. EMBO J 2007, 26:3180-90.
44. Takaki H, Oshiumi H, Sasai M, Kawanishi T, Matsumoto M, Seya T. Oligomerized TICAM-1(TRIF) in the cytoplasm recruits nuclear Bs69 to enhance NF-kappaB activation and type I IFN induction. Eur J Immunol. 2009, 39:3469-76.
45. Sasai M, Oshiumi H, Funami K, Matsumoto M, Seya T. Direct binding of TRAF2 and TRAF6 to TICAM-1/TRIF adaptor of the Toll-like receptor 3/4 pathway. Molec. Immunol 2010, in press
46. Honda K, Ohba Y, Yanai H. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005, 434:1035-40.
47. Geissmann F, Prost C, Monnet JP, Dy M, Brousse N, Hermine O. Transforming growth factor beta1, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J Exp Med 1998, 187:961-6.
48. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res 2003, 90:127-56.
49. Chen Z, O'Shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008, 41(2):87-102.
50. Yamazaki S, Dudziak D, Heidkamp GF. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J Immunol 2008, 181:6923-33.
51. Miyake T, Kumagai Y, Kato H. Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways. J Immunol 2009, 183:2522-8.
52. Tezuka H, Abe Y, Iwata M. Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells. Nature 2007, 448:929-33.
53. Atarashi K, Nishimura J, Shima T. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008, 455:808-12.
54. Ebihara T, Azuma M, Oshiumi H. Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells. Hepatology 2008, 48:48-58.
55. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999, 353:1689-94.
56. Kodama K, Higashiyama M, Takami K. Innate immune therapy with a Bacillus Calmette-Guérin cell wall skeleton after radical surgery for non-small cell lung cancer: a case-control study. Surg Today 2009, 39:194-200.
57. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-15.
58. Nakao Y, Funami K, Kikkawa S. Surface-expressed TLR 6 Participates in the Recognition of Diacylated Lipopeptide and Peptidoglycan in Human Cells. J Immunol 2005, 174:1566-73.
59. Uehori J, Matsumoto M, Tsuji S. Simultaneous blocking of human Toll-like receptor 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin (BCG)-peptidoglycan (PGN). Infect Immun 2003, 71:4238-49.
60. Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun 2002, 293:1364-9.
61. Bosisio D, Polentarutti N, Sironi M. Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon-gamma: a molecular basis for priming and synergism with bacterial lipopolysaccharide. Blood 2002, 99:3427-31.
62. Nishiguchi M, Matsumoto M, Takao T. Mycoplasma fermentans lipoprotein M161Ag-induced cell activation is mediated by Toll-like receptor 2: role of N-terminal hydrophobic portion in its multiple functions. J Immunol 2001, 166:2610-6.
63. Matsuo-Tanabe M, Kawamoto T, Tanida S, Matsumoto M, Seya T. Toll-like receptor 2 agonists with unique properties synthesized with reference to a product of Streptosporangium. Immunology 2004, 235-41.
64. Brandenburg K, Lindner B, Schromm A. Physicochemical characteristics of triacyl lipid A partial structure OM-174 in relation to biological activity. Eur J Biochem 2000, 267:3370-7.
65. Murata M. Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci 2008, 99:1435-40.
66. Shingai M, Ebihara T, Begum NA. Differential type I IFN-inducing abilities of wild-type versus vaccine strains of measles virus. J Immunol 2007, 179:6123-33.
67. Sugiyama T, Hoshino K, Saito M. Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7. Int Immunol 2008, 20:1-9.
68. Navabi H, Jasani B, Reece A. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 2009, 27:107-15.